Drug Clinical Trials List

Study Title	Study Sponsor	Status	Study Drug	Trial Phase	Study Protocol Number	Site
A Multinational, Randomised, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Ticagrelor Twice Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Stroke in Patients With Type 2 Diabetes Mellitus (THEMIS - Effect of Ticagrelor on Health Outcomes in diabEtes Mellitus Patients Intervention Study)	AstraZeneca	Ongoing	Ticagrelor	3b	D513BC00001	King Khalid University Hospital (Riyadh), King Fahad Specialist Hospital (Dammam), King Faisal Specialist Hospital and Research Center (Riyadh), King Faisal Specialist Hospital and Research Center (Jeddah), King Fahad Medical City (Riyadh), King Abdulaziz Medical City NG (Riyadh), King Fahad University Hospital (Al-Khobar), Saud Al-Babtain Cardiac Center (Dammam)
"An Open-Label, Multinational, Multicenter, Phase IIIB Study With Subcutaneus Administration Of Trastuzumab In Patient With Her2-Positive Early Breast Cancer To Evaluate Patient Satisfaction"	Roche	Ongoing	Trastuzumab SC	3b	ML28851	King Khalid University Hospital (Riyadh), International Medical Center (Jeddah)
A 52-week, double-blind, randomised, multi-centre, phase III, parallel-group study in patients 12 years and older with asthma, evaluating the efficacy and safety of Symbicort (budesonide/formoterol) Turbuhaler 160/4.5 μg 'as needed' compared with Pulmicort (budesonide) Turbuhaler 200 μg twice daily plus terbutaline Turbuhaler 0.4 mg 'as needed'	AstraZeneca	Ongoing	Budesonide / Formoterol / Budesonide / Terbutaline	3	D589SC00003	Armed Forces Hospital (Dhahran), King Fahad Specialist Hospital (Dammam), King Khalid University Hospital (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh), King Fahad University Hospital (Al-Khobar), King Faisal Specialist Hospital and Research Center (Jeddah)
A Randomized, Double-blind, Multicenter, Phase III Study of Everolimus (RAD001) Plus Best Supportive Care Versus Placebo Plus Best Supportive Care in the Treatment of Patients With Advanced NET of GI or Lung Origin - RADIANT-4	Novartis	Ongoing	Everolimus/ Afinitor	3	CRAD001T2302	King Faisal Specialist Hospital and Research Center (Riyadh)
A Randomized, double-blind, placebo-controlled, multicenter phase III study of RAD001 Adjuvant Therapy in Poor Risk with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching PlaceboAfter Patients Have Achieved Complete Response with First-line Rituximab Chemotherapy	Novartis	Completed	Everolimus	3	CRAD001N2301	King Fahad Specialist Hospital (Dammam), King Abdulaziz Medical City NG (Riyadh), King Abdulaziz Medical City NG (Jeddah)
An Open-lable, Multicenter, Phase 2 Study to Evaluate Everolimus as Monotherapy Treatment for patients with Metastatic Recurrent and/or Unresectable Renall Cell Carcinoma (EVERMORE).	Novartis	Ongoing	Everolimus	2	CRAD001LIC01	King Faisal Specialist Hospital and Research Center (Riyadh)
A 24 month, randomized, controlled, study to evalute the efficacy and safety of concentration-controlled everolimus plus reduced tacrolimus in recipients of living donor liver transplants.	Novartis	Ongoing	Everolimus / reduced tacrolimus / Tacrolimus	3	CRAD001H2307	King Faisal Specialist Hospital and Research Center (Riyadh)
A Phase III, Multicenter, Randomized, parallel-group study to asses the efficacy and saftey of double-blind pasireotide LAR 40 mg and pasireotide LAR 60 mg versus open lable octreotide LAR or lanreotide ATG in patients with inadequately controlled acromegaly.	Novartis	Ongoing	Pasireotide	3	CSOM230C2402	King Abdulaziz Medical City NG (Riyadh), King Faisal Specialist Hospital and Research Center (Riyadh), King Abdulaziz Medical City NG (Jeddah)
An Open-lable, Multicenter, expanded access study of INC424 for patients with primary myelofibrosis (PMF) or post polycythemia myelofibrosis (PPV MF) or post-essential thrombocythemia myelofibrosis (PET-MF).	Novartis	Ongoing	Ruxolitinib	3b	CINC424A2401	King Abdulaziz Medical City NG (Riyadh), King Abdulaziz Medical City NG (Jeddah)
A Randomized, Open-label, Multicentral, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)	Novartis	Ongoing	Deferasirox / Defearisox new formula	2	CICL670F2201	King Khalid University Hospital (Riyadh), King Fahad University Hospital (Al-Khobar), King Abdulaziz University Hospital (Jeddah), King Fahad Specialist Hospital (Dammam)